Rare Disease Biotech Setara Starts Out With $90M and a Lead Drug in the Clinic

Setara Biosciences’ lead program is a potential treatment for the rare neuromuscular disorder Charcot-Marie-Tooth disease type 2C and the prevalent condition overactive bladder. This small molecule came from Actio Biosciences, which was recently acquired by Jazz Pharmaceuticals. The post Rare Disease Biotech Setara Starts Out With $90M and a Lead Drug in the Clinic appeared…

Read More

Prestige Is a Business Model

An employer that treats board disclosure, community benefit reporting, and contracting terms as three separate conversations is missing that they are the same conversation. The post Prestige Is a Business Model appeared first on MedCity News.

Read More

9 Things to Watch for the 2027 ACA Open Enrollment Period 

The ACA Marketplace Open Enrollment season begins November 1, bringing higher out-of-pocket premium payments, new eligibility requirements for certain groups, and state efforts to offset premium increases following the expiration of enhanced premium tax credits. Read our analysis of what these and other changes could mean for enrollees.

Read More